



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
- (21) **International Application Number:**
PCT/US2023/069710
- (22) **International Filing Date:**
06 July 2023 (06.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/367,953 08 July 2022 (08.07.2022) US
- (71) **Applicant:** **IMAGINAB, INC.** [US/US]; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US).
- (72) **Inventors:** **MASCIONI, Alessandro**; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). **JIA, Fang**; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). **DE SOUZA, CORDEIRO, Leticia, Maria**;

423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). **ATKINSON, Kelley, C.**; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). **JOYCE, Patrick**; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US). **AIVAZIAN, Argin**; 423 Hindry Avenue, Suite D, Inglewood, California 90301 (US).


- (74) **Agent:** **LOZAN, Vladimir, S.**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** DLL3 ANTIGEN BINDING CONSTRUCTS

FIG. 10

Binding to tumor cells (Flow Cytometry):



- (57) **Abstract:** Provided herein are components for antigen binding constructs, including antibodies and fragments thereof, such as minibodies and cys-diabodies, that bind to a target molecule, for example, DLL3. In some embodiments, these components are novel complementarity-determining region (CDR) sequences and/or sequences associated with and/or part of the CDR sequence. In some embodiments, these components are novel framework region (FR) sequences and/or sequences associated with and/or part of the FR sequence. These CDR and FR sequences can provide various benefits. Also provided herein are the antigen binding constructs (such as, minibodies, cys-diabodies, etc.) that include one or more of the CDR or FR sequences or subsequences provided herein.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*